The Committee for Medicinal Products for Human Use (CHMP), the European Commission's (EC) advisory body, issued a positive opinion for Novartis AG's (ADR) (NYSE:NVS) Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis.
The Committee for Medicinal Products for Human Use (CHMP), the European Commission's (EC) advisory body, issued a positive opinion for Novartis AG's (ADR) (NYSE:NVS) Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis.
Share this Article
Recommended